Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures

Share Article

Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures

Nanotherapeutics, Inc., announced it has been awarded a Department of Defense’s (DOD) contract to establish Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) capability dedicated to meet the needs of the DOD. The MCM ADM capabilities established by Nanotherapeutics will allow the DOD to more efficiently and expeditiously develop Medical Countermeasures (MCM) to protect and treat military populations against chemical, biological, radiological, and nuclear (CBRN) attacks and outbreaks of naturally occurring emerging and genetically engineered infectious diseases.

The contract was granted to Nanotherapeutics, as the prime contractor, and its industry partners after a highly competitive bid process. The ultimate goal for the award is to reduce the overall time and cost associated with the development and manufacturing of Food and Drug Administration approved MCMs.

Headquartered in Alachua, FL, Nanotherapeutics will integrate into a new state-of-the-art facility flexible, single use, disposable equipment that can provide our military’s national security requirements for MCMs now and in the foreseeable future.

Nanotherapeutics has assembled a world class team of partners from throughout the United States to apply new biomanufacturing technologies with existing manufacturing capabilities for small molecule and biologic products that will provide the DOD with the ability to rapidly respond to CBRN events.

About Nanotherapeutics
Nanotherapeutics, Inc. is a privately held biopharmaceutical company with a major focus on developing a diversified proprietary pipeline of products having both biodefense and medical applications. Products under development include biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infectives, vaccines and orthopedics. The Company has one FDA cleared injectable biologic, NanoFUSE® DBM used by orthopedic surgeons as bone graft filler. Nanotherapeutics has in-house cGMP manufacturing, formulation, and expertise in pre-clinical and clinical product development as well as clinical trial management to support its products. Established in 1999, the Company employs several proprietary platform technologies to manipulate and enhance the properties of drug candidates. For more information, visit the Company website at http://www.nanotherapeutics.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Ascani
Nanotherapeutics, Inc
386-462-9663
Email >
Visit website